Matthew M. Ames
YOU?
Author Swipe
Package<b>CovRegpy</b>: Regularized covariance regression and forecasting in<b>Python</b> Open
This paper will outline the functionality available in the CovRegpy package which was written for actuarial practitioners, wealth managers, fund managers, and portfolio analysts in the language of Python 3.11 . The objective is to develop …
Long/Short Equity Risk Premia Parity Portfolios via Implicit Factors in Regularized Covariance Regression Open
A robust time series basis decomposition and non-stationary trend extraction technique, known as Empirical Mode Decomposition (EMD), will be combined with Regularised Covariance Regression (RCR) to produce a novel covariance forecasting te…
View article: Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer Open
Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine…
Hybrid ARDL-MIDAS-Transformer time-series regressions for multi-topic crypto market sentiment driven by price and technology factors Open
This paper develops a novel hybrid Autoregressive Distributed Lag Mixed Data Sampling (ARDL-MIDAS) model that integrates both deep neural network multi-head attention Transformer mechanisms, and a number of covariates, including sophistica…
Package AdvEMDpy: Algorithmic variations of empirical mode decomposition in Python Open
This work presents a $\textsf{Python}$ EMD package named AdvEMDpy that is both more flexible and generalises existing empirical mode decomposition (EMD) packages in $\textsf{Python}$ , $\textsf{R}$ , and $\textsf{MATLAB}$ . It is aimed spe…
Data from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Open
SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 che…
View article: Supplementary Figure S3 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S3 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S3 - PDF file 93K, ZNF423 and BRCA1 expression in LCLs for variant and wild type genotypes
View article: Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S2 - PDF file 17K, ZNF423 expression in two cell lines
Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Open
Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668
View article: Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S2 - PDF file 17K, ZNF423 expression in two cell lines
View article: Supplementary Figure S4 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S4 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S4 - PDF file 23K, CTSO and BRCA1 expression in LCLs with variant and wild type genotypes
View article: Supplementary Figure S3 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S3 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S3 - PDF file 93K, ZNF423 and BRCA1 expression in LCLs for variant and wild type genotypes
View article: Supplementary Figure S4 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S4 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S4 - PDF file 23K, CTSO and BRCA1 expression in LCLs with variant and wild type genotypes
Data from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Open
SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 che…
View article: Supplementary Figure S1 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S1 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S1 - PDF file 43K, Q-Q plot
View article: Supplementary Figure S5 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S5 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S5 - PDF file 147K, ChIP assay for known genotypes of rs6810983 showing functional disruption of an estrogen response element
View article: Supplementary Figure S1 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S1 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S1 - PDF file 43K, Q-Q plot
View article: Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Material - PDF file 131K, Provision of Supplementary material relating to methods, tables for patient characteristics, SNP-covariate interactions, SNP effects on time to breast cancer, top SNPs on chromosomes 4 and 16, and su…
View article: Supplementary Figure S5 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Figure S5 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Figure S5 - PDF file 147K, ChIP assay for known genotypes of rs6810983 showing functional disruption of an estrogen response element
Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Open
Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668
View article: Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
Supplementary Material - PDF file 131K, Provision of Supplementary material relating to methods, tables for patient characteristics, SNP-covariate interactions, SNP effects on time to breast cancer, top SNPs on chromosomes 4 and 16, and su…
View article: Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We a…
View article: Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention Open
The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We a…
Supplementary Table 2 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 Open
PDF file, 62K, Supplementary Table 2: Grade 3 or 4 events with relationship unrelated to unlikely to combination therapy (Vorinostat + TMZ).
View article: Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Open
PDF file - 41K, Pharmacokinetic parameters of vorinostat and its major metabolites.
Supplementary Table 1 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 Open
PDF file, 80K, Supplementary Table 1: Temozolomide 150 mg/m2 Pharmacokinetic Parameters (first cycle).
Data from Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics Open
Purpose: Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to stu…
View article: Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Open
PDF file - 42K, Alvocidib pharmacokinetic parameters.
View article: Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Open
PDF file - 45K